Log in

NASDAQ:CCXIChemoCentryx Stock Price, Forecast & News

$58.01
-0.14 (-0.24 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$55.80
Now: $58.01
$58.61
50-Day Range
$53.79
MA: $59.35
$65.07
52-Week Range
$6.16
Now: $58.01
$65.43
Volume546,343 shs
Average Volume986,993 shs
Market Capitalization$3.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.04
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
Read More
ChemoCentryx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.6Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.13 million
Book Value$1.14 per share

Profitability

Net Income$-55,490,000.00
Net Margins-192.93%

Miscellaneous

Employees82
Market Cap$3.59 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

How has ChemoCentryx's stock been impacted by COVID-19 (Coronavirus)?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CCXI stock has increased by 39.6% and is now trading at $58.01. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ChemoCentryx?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ChemoCentryx.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for ChemoCentryx.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) released its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05. The biopharmaceutical company earned $6.01 million during the quarter, compared to analysts' expectations of $8.90 million. ChemoCentryx had a negative net margin of 192.93% and a negative return on equity of 100.55%. View ChemoCentryx's earnings history.

What price target have analysts set for CCXI?

9 Wall Street analysts have issued twelve-month target prices for ChemoCentryx's stock. Their forecasts range from $54.00 to $102.00. On average, they expect ChemoCentryx's stock price to reach $70.11 in the next year. This suggests a possible upside of 20.9% from the stock's current price. View analysts' price targets for ChemoCentryx.

Has ChemoCentryx been receiving favorable news coverage?

Media stories about CCXI stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ChemoCentryx earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about ChemoCentryx.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a increase in short interest in June. As of June 15th, there was short interest totaling 3,790,000 shares, an increase of 34.4% from the May 31st total of 2,820,000 shares. Based on an average daily trading volume, of 661,800 shares, the short-interest ratio is currently 5.7 days. Approximately 8.6% of the shares of the company are short sold. View ChemoCentryx's Current Options Chain.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 61, Pay $968.76k)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 57, Pay $696.65k)
  • Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 59, Pay $563.8k)
  • Ms. Kari E. Leetch, Sr. VP of HR
  • Dr. Catherine Lee Kelleher, Sr. VP of Clinical Devel.

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $58.01.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $3.59 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.